Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials
Brett King, Catherine Maari, Edward Lain, et al.
American Journal of Clinical Dermatology (2021) Vol. 22, Iss. 3, pp. 395-405
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

JAK inhibitors in the treatment of atopic dermatitis
Raj Chovatiya, Amy S. Paller
Journal of Allergy and Clinical Immunology (2021) Vol. 148, Iss. 4, pp. 927-940
Open Access | Times Cited: 229
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022)
Adarsh Bhimraj, Rebecca L. Morgan, Amy Hirsch Shumaker, et al.
Clinical Infectious Diseases (2022) Vol. 78, Iss. 7, pp. e250-e349
Open Access | Times Cited: 126
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Brett King, Jennifer Soung, Christos Tziotzios, et al.
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 2, pp. 299-314
Open Access | Times Cited: 20
Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies
Kim Papp, Jacek C. Szepietowski, Leon Kircik, et al.
Journal of the American Academy of Dermatology (2022) Vol. 88, Iss. 5, pp. 1008-1016
Closed Access | Times Cited: 50
Current and Emerging Strategies to Inhibit Type 2 Inflammation in Atopic Dermatitis
El‐Bdaoui Haddad, Sonya Cyr, Kazuhiko Arima, et al.
Dermatology and Therapy (2022) Vol. 12, Iss. 7, pp. 1501-1533
Open Access | Times Cited: 45
Association of Risk of Incident Venous Thromboembolism With Atopic Dermatitis and Treatment With Janus Kinase Inhibitors
Tai‐Li Chen, Ling-Ling Lee, Huei‐Kai Huang, et al.
JAMA Dermatology (2022) Vol. 158, Iss. 11, pp. 1254-1254
Open Access | Times Cited: 43
A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19
Thomas Bieber, Eugen Feist, Alan D. Irvine, et al.
Advances in Therapy (2022) Vol. 39, Iss. 11, pp. 4910-4960
Open Access | Times Cited: 39
Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitors in Immune-Mediated Inflammatory Skin Diseases
Jenne P. Ingrassia, Muhammad Haisum Maqsood, Joel M. Gelfand, et al.
JAMA Dermatology (2023) Vol. 160, Iss. 1, pp. 28-28
Closed Access | Times Cited: 30
Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs
Lina Alhanshali, Michael G Buontempo, Kristen I. Lo Sicco, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 803-820
Open Access | Times Cited: 26
JAK in the [Black] Box: A Dermatology Perspective on Systemic JAK Inhibitor Safety
Sarina B. Elmariah, Jeffrey S. Smith, Joseph F. Merola
American Journal of Clinical Dermatology (2022) Vol. 23, Iss. 4, pp. 427-431
Closed Access | Times Cited: 37
Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials
Thomas Bieber, Norito Katoh, Eric L. Simpson, et al.
Journal of Dermatological Treatment (2022) Vol. 34, Iss. 1
Open Access | Times Cited: 31
Baricitinib: The First Jak Inhibitor Approved in Europe for the Treatment of Moderate to Severe Atopic Dermatitis in Adult Patients
Giulia Radi, Oriana Simonetti, Giulio Rizzetto, et al.
Healthcare (2021) Vol. 9, Iss. 11, pp. 1575-1575
Open Access | Times Cited: 33
Janus kinase inhibitors in autoimmune bullous diseases
Dawei Huang, Yuexin Zhang, Luyang Kong, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 15
Insights into atopic dermatitis pathogenesis lead to newly approved systemic therapies
Anna M. Trier, Brian Kim
British Journal of Dermatology (2022) Vol. 188, Iss. 6, pp. 698-708
Open Access | Times Cited: 20
Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial
Jacob P. Thyssen, Thomas Werfel, S. Barbarot, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 9
Long-Term Safety Profile and Off-Label Use of JAK Inhibitors in Dermatological Disorders
L. Corbella‐Bagot, Constanza Riquelme‐Mc Loughlin, D. Morgado-Carrasco
Actas Dermo-Sifiliográficas (2023) Vol. 114, Iss. 9, pp. 784-801
Open Access | Times Cited: 9
Off-label use of Baricitinib improves moderate and severe atopic dermatitis in China through inhibiting MAPK and PI3K/Akt/mTOR pathway via targeting JAK-STAT signaling of CD4+ cells
Shuang Chen, Caihua Li, Zeng Tu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 3
Janus Kinase Inhibitors: A Promising Therapeutic Option for Allergic Contact Dermatitis
Hadley Johnson
Cutis (2023) Vol. 111, Iss. 2
Open Access | Times Cited: 7
Application of JAK inhibitors in paradoxical reaction through immune-related dermatoses
Yaxin Zhang, Guan Jiang
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Treatment of Atopic Dermatitis in Children
Faten Sid Idris
Cureus (2024)
Open Access | Times Cited: 2
JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
Albertine Beard, Shannon C. Trotter
Journal of Family Medicine and Primary Care (2024) Vol. 13, Iss. 10, pp. 4128-4134
Open Access | Times Cited: 2
Infections with Herpes simplex and Varicella zoster virus
Larissa Wilms, Katharina Weßollek, Theresa Barbara Peeters, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2022) Vol. 20, Iss. 10, pp. 1327-1351
Open Access | Times Cited: 10
Infectious Adverse Events in Patients with Atopic Dermatitis Treated with Baricitinib
Flaminia Antonelli, Dalma Malvaso, Giacomo Caldarola, et al.
Immunotherapy (2023) Vol. 15, Iss. 18, pp. 1521-1529
Closed Access | Times Cited: 5
Pooled Analysis of Baricitinib Tolerability in Patients With Atopic Dermatitis in Relation to Acne, Headache, and Gastrointestinal Events From 8 Clinical Trials
Andreas Wollenberg, Leon Kircik, Eric L. Simpson, et al.
Dermatitis (2023) Vol. 34, Iss. 4, pp. 308-314
Open Access | Times Cited: 4
[Artículo traducido] Perfil de seguridad a largo plazo y usos fuera de indicación de los inhibidores de JAK en dermatología
L. Corbella‐Bagot, Constanza Riquelme‐Mc Loughlin, D. Morgado-Carrasco
Actas Dermo-Sifiliográficas (2023) Vol. 114, Iss. 9, pp. T784-T801
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top